EXPAREL IPSA Block in Knee Arthroplasty

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

May 20, 2025

Study Completion Date

December 31, 2025

Conditions
Pain, PostoperativeOsteo Arthritis Knee
Interventions
DRUG

Exparel

20 milliliter (mL) EXPAREL with 20mL bupivacaine hydrochloride (HCL) 0.5% will be expanded. An 18-gauge bevel needle will be introduced through the capsular pocket at 1 to 2cm proximal to the adductor tubercle at the proximal border of the posteromedial femoral condyle. The needle will be angled proximally and posteriorly, and then advanced to contact the posteromedial capsule. A 20mL bolus of the study drug admixture will be administered. The remaining 20mL of the study drug admixture will be administered to the anterior and lateral knee structures with approximately 1 to 1.5mL administered with each stick to the intended area.

Trial Locations (1)

38138

Campbell Clinic, Germantown

All Listed Sponsors
lead

Campbell Clinic

OTHER